Changes in AOL Lymphoma Chat
AOL has been going through some major changes, especially since being bought by Time-Warner. The latest is that AOL will no longer have volunteer hosts (aka Community Leaders) for their chats. As far as we know, the chats will remain intact. AOL has discontinued hosts' abilities to prevent disruption in a chat room. AOL's philosophy is that anyone can welcome people and control experiences in a chat.
Many years ago I was co-host of the Cancer Survivors chat on AOL. I later cohosted Cancer Survivors Comfy Couch then I formed a separate Lymphoma Chat. For much of that time I hosted the chat with Susan, a fellow lymphoma survivor. Many weeks I would wake up early in Helsinki and host the chat with Susan in the US. Isn't the Internet great! Lymphoma Chat should still be in its usual time slot. Susan intends to still be there but will no longer be a host. :-( The changes will happen on June 8th.
For you AOL members: LYMPHOMA CHAT, Tuesdays 9:00 PM Eastern Time, Glennas Garden (AOL URL aol://2719:3-1072-Glennas Garden/). Lymphoma survivors and their families and friends are all welcome.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
